Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy
Sponsor: Asana BioSciences
Listed as NCT03728504, this PHASE2 trial focuses on Chronic Hand Dermatitis and remains completed. Sponsored by Asana BioSciences, it has been updated 16 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
16 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Completed PHASE2
-
Mar 2023 — Jun 2023 [monthly]
Completed PHASE2
▶ Show 11 earlier versions
-
Feb 2023 — Mar 2023 [monthly]
Completed PHASE2
-
Jan 2021 — Feb 2023 [monthly]
Completed PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Completed PHASE2
Status: Terminated → Completed
-
Jun 2020 — Jul 2020 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Feb 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Jun 2019 — Oct 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — May 2019 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Feb 2019 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Asana BioSciences
For direct contact, visit the study record on ClinicalTrials.gov .